The results were shown in the first randomized phase II study comparing trastuzumab-DM1 (T-DM1) to Herceptin (trastuzumab) plus chemotherapy (docetaxel), the current standard of care for first line HER2-positive metastatic breast cancer.
"That was a higher standard than my previous matches and it's a big positive for me heading into the quarter-finals, " said Djokovic who reached the quarter-finals in all four Grand Slams last year.